Amaros Launches Interventional Glaucoma Network to Advance Evidence in Interventional Glaucoma

Company also appoints Mark Packer, MD, as Chief Medical Officer and Jai Parekh, MD, as Chief Strategy Officer

ATHERTON, Calif.--(BUSINESS WIRE)--Amaros, Inc. (www.amaros.ai), a leader in ophthalmic precision intelligence and the developer of the AI-powered AmarosEngine™ platform, today announced the launch of its Interventional Glaucoma Network (IGN), a clinician-led initiative designed to generate high-quality clinical and real-world evidence to support advances in interventional glaucoma care.

The Amaros IGN convenes recognized leaders in glaucoma and anterior segment care to support programs in clinical research, outcomes intelligence, and generation of real-world evidence. Powered by AmarosEngine, the network is intended to enable rigorous study design, faster patient identification and enrollment, and more consistent collection of outcomes data across procedures and treatments.

The founding IGN members include:

• Iqbal “Ike” Ahmed, FRCSC
• Jason E. Bacharach, MD
• John P. Berdahl, MD
• Cathleen M. McCabe, MD

“Interventional glaucoma is evolving rapidly, but the supporting evidence infrastructure hasn’t kept pace,” said Ben Toker, co-founder and President of Amaros. “Our IGN brings together the field’s most influential clinicians with the precision intelligence capabilities of AmarosEngine to help close that gap. The result should be faster learning, clearer outcomes, and more consistent evidence generation across interventional glaucoma.”

AmarosEngine is a proprietary precision intelligence platform that integrates electronic health records, practice management systems, images, and claims data into a single, structured ecosystem. Operating within the clinical environment, the platform delivers real-time, actionable insights across the eyecare continuum – from accelerating clinical trial enrollment and generating real-world evidence to assisting to optimize treatment strategies.

“AmarosEngine was built to transform complex ophthalmic data into actionable clinical intelligence,” said Vartan Ghazarossian, Ph.D., co-founder and CEO of Amaros. “The launch of the Amaros IGN marks an important milestone in our expansion beyond retina into glaucoma and reinforces our commitment to rigorous, clinician-driven evidence generation.”

Amaros also announced two senior leadership appointments to support its expanding clinical and strategic programs:

• Mark Packer, MD, Chief Medical Officer (CMO) – Dr. Packer brings deep experience in anterior segment surgery, innovation, and clinical research. As CMO, he will lead clinical strategy, evidence program design, and medical affairs across Amaros’ growing therapeutic focus areas.
• Jai Parekh, MD, Chief Strategy Officer (CSO) – Dr. Parekh is a recognized leader in glaucoma care and health care strategy. As CSO, he will help guide Amaros’ commercial strategy, strategic partnerships and growth initiatives as the company scales its platform and evidence programs.

About Amaros

Founded in 2019 in Silicon Valley, Amaros, Inc. (www.amaros.ai) is a leader in ophthalmic precision intelligence. Its flagship platform, AmarosEngine, integrates electronic medical records, images, genomics, clinician notes, outcomes, and claims into structured information that delivers real-time, actionable insights. From accelerating clinical trials to generating real-world evidence to supporting treatment optimization, Amaros empowers physicians, researchers, and industry partners across the eyecare continuum to make smarter decisions, faster.